Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine.
about
Antiepileptic drugs and bone metabolismAdverse effects of antiepileptic drugs on bone mineral density in children.Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism.Antiepileptic drugs and bone metabolism in children: data from 128 patients.Histone deacetylases in skeletal development and bone mass maintenance.Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.Hdac-mediated control of endochondral and intramembranous ossificationPotential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children- a medical center experience.Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report.Epilepsy and vitamin D.Epilepsy treatment by sacrificing vitamin D.Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy.Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs.Bone Density in Adolescents and Young Adults with Autism Spectrum DisordersCarbamazepine does not alter biochemical parameters of bone turnover in healthy male adults.Impaired bone and muscle development in young people treated with antiepileptic drugs.
P2860
Q21245075-3BE1A4CF-9410-46EC-99E2-745D149BD777Q33283736-5AEB7D28-9330-45AB-B9D7-4C391C068753Q33290977-168862D7-6A23-418B-B36E-35DDFD0A2DBEQ34253275-0618236A-1E8E-421E-A729-4A54B71D1BB4Q34612849-EBA91235-F0CE-4AF9-A888-B115ACA81812Q34810920-4491FCF3-6D5E-49C6-B960-4948F2BF8CC1Q35556841-2D335370-47D6-46AE-9DF5-3AE60CEA50C9Q36007883-663FEAD6-1EEB-4B86-AA48-4EB8CDD6B554Q37338208-B3F557AA-44E7-46A2-BC8F-52D26A409157Q38142332-DEF525B9-ED65-4D7D-8CDF-97D529882CD0Q38205010-986A9C25-8330-4BE2-AB40-F39822047055Q38310689-069AD7A5-9F63-4994-8E2A-E8DD30A56F57Q38640619-7CE08188-B3C5-46C9-9B26-29D40BACFAB9Q39524375-BADC1D9E-B281-4566-9ADD-71579B251805Q44521539-7925F009-A193-47EC-AB29-F08CFA016D71Q48021389-9E2B4CC6-683E-4684-BCC1-E858B6B8E638
P2860
Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@ast
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@en
type
label
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@ast
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@en
prefLabel
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@ast
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@en
P2093
P356
P1433
P1476
Analysis of the musculoskeleta ...... alproic acid or carbamazepine.
@en
P2093
Herkenrath P
Rieger-Wettengl G
Schauseil-Zipf U
Schoenau E
Tutlewski B
P356
10.1542/PEDS.108.6.E107
P407
P577
2001-12-01T00:00:00Z